 |
 |
 |
 |
 |
 |
Toronto, March 27, 2024 – The Structural Genomics Consortium (SGC) is pleased to announce Dr. Hui Peng has joined the SGC-Toronto as a Principal Investigator.
SGC Press Releases
Wednesday 27th March 2024
Thursday 14th March 2024
Monday 4th March 2024
SGC's CIHR Award recipients. (L-R): Drs. Cheryl Arrowsmith, Matthieu Schapira, and Dalia Barsyte-Lovejoy.
The Canadian Institutes of Health Research (CIHR) has recently released the results of its Fall 2023 Project Grant funding competition. This competition aims to provide financial support to projects that will advance knowledge, research methodologies, patient care, and overall health outcomes.
Tuesday 27th February 2024
Frankfurt, February 26, 2024– The Structural Genomics Consortium (SGC) at Goethe University Frankfurt am Main has secured a significant €11.8 million in funding from the German Cancer Aid for the development of new, targeted cancer drugs, with a particular emphasis on rare tumor diseases.
Wednesday 10th January 2024
[Toronto, January 10, 2024] - Professor Benjamin Haibe-Kains has joined the Structural Genomics Consortium as the Head of Data Science to further support SGC’s ambition to generate high-quality and reproducible data. In his new role, Dr. Haibe-Kains will establish a robust mechanism to ensure transparency, interoperability, and accessibility of SGC’s data for machine learning and pattern recognition.
Thursday 28th September 2023
Thursday 28th September 2023
TORONTO, Canada, October 3, 2023 – The Structural Genomics Consortium (SGC) today announced that it has entered into a partnership with Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH). HitGen will utilize its DNA-encoded library (DEL) technology platform, specifically OpenDEL™, to screen under-represented targets chosen by SGC.
Wednesday 10th May 2023
North Carolina, May 10, 2023 – The Structural Genomics Consortium (SGC) at the University of North Carolina at Chapel Hill has been awarded a $1.5 million grant from the U.S Department of Defense to support drug discovery efforts aimed at the investigation of small molecules that could potentially serve as new treatment options for patients with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s Disease.
Tuesday 2nd May 2023
The University of Toronto's Acceleration Consortium has received a record-breaking $200 million Canada First Research Excellence Fund (CFREF) to advance the discovery of new materials and molecules. This award marks the largest single federal research grant to a university in Canadian history.
Tuesday 16th November 2021
Pages
